The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

BMO Capital says that today’s appeals court decision to affirm the denial of Regeneron’s (REGN) preliminary injunction against Amgen (AMGN) in ...

Regeneron (REGN) faces a 3% stock drop after losing an appeals case over its Eylea drug patents against Amgen (AMGN).

An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Eylea has been a significant revenue driver for Regeneron, and any potential impact on its sales due to competition from biosimilars is closely watched by investors. The court’s ruling thus represents ...

had infringed on U.S. Patent 11,084,865, claimed to cover a vial containing Eylea. As a result of the ruling, Amgen, which produces a biosimilar for Eylea, saw its shares increase by as much as 0.5%.

The US Court of Appeals for the Federal Circuit on Friday ruled against Regeneron in a closely-watched patent infringement ...

Eylea, which Regeneron Pharmaceuticals ... ranks tenth on our list of the 11 best pharma stocks to buy according to hedge funds. Amgen Inc. (NASDAQ:AMGN) is a biotechnology company that discovers ...

Regeneron Pharmaceuticals Inc. failed to convince the Federal Circuit to block an Amgen Inc. biosimilar of Eylea while the competitors duke it out in a patent lawsuit. Amgen’s biosimilar formulation ...